AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Ubrelvy (ubrogepant) by Quarter
Ubrelvy (ubrogepant) — International operational (constant-currency) growth YoY (%) (%)
AbbVie Ubrelvy (ubrogepant): 52.5% in Q2 2026, down 24.2 pts from a year earlier.
Latest, Q2 2026
52.5%
Period ended Jun 30, 2026
Change on a year earlier
-24.2 pts
76.7% in Q2 2025
History
8 quarters
Since Q2 2024
Sources
8
Documents cited below
Where the Q2 2026 figure comes from
“|| Ubrelvy | 379 | 13 | 392 | 15.0 | 54.9 | 16.0 | 52.5 | 15.9”
Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Reported in Form 8-K Key Product Revenues Schedule.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Ubrelvy (ubrogepant) — International operational (constant-currency) growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 52.5% | -24.2 pts | Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | 22.9% | -6.4 pts | Form 8-K (abbv-20260331xexhibit991.htm, filed 2026-04-29) ↗ |
| Q4 2025 | Dec 31, 2025 | -3.0% | -69.2 pts | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| Q3 2025 | Sep 30, 2025 | 34.2% | – | Form 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗ |
| Q2 2025 | Jun 30, 2025 | 76.7% | -5.6 pts | Form 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗ |
| Q1 2025 | Mar 31, 2025 | 29.3% | – | Form 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗ |
| Q4 2024 | Dec 31, 2024 | 66.2% | – | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| Q2 2024 | Jun 30, 2024 | 82.3% | – | Form 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗ |
Cite this data
StockData. (2026). AbbVie Ubrelvy (ubrogepant) (%), quarterly Q2 2024–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ubrelvy-intl-op-yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.